601-610 of 639 results
Allens advises Healthscope on sale of Australian pathology business
Allens has acted for one of Australia's leading private healthcare operators, Healthscope Limited, on the sale of its Australian pathology operations to Crescent Capital Partners for $105 million. ...
Linklaters and Allens advises consortium on Myanmar telco deal
Alliance partners Linklaters and Allens have advised the KDDI Corporation–Sumitomo Corporation consortium on its agreement with Myanmar government agency Myanma Posts & Telecommunications to jointl ...
Allens advises on successful $2.6bn bid for NSW LPI concession
Allens has advised Australian Registry Investments (ARI) – a consortium led by Hastings Funds Management and First State Super – on its successful $2.6 billion bid to operate a 35-year concession o ...
Clearer picture: Allens advises Foxtel on Channel 10 acquisitions
Allens has advised Australian pay TV operator Foxtel on the competition aspects of its proposed tie-up with free-to-air television station Channel 10. The deal cleared a major hurdle last week when ...
Big data: Allens advises M2 Group on proposed $3 billion merger
Allens has advised M2 Group Ltd on its proposed $3 billion merger with Vocus Communications. Under the proposed merger, announced today, M2 Group shareholders will receive 1.625 Vocus shares for ea ...
Allens advises Aristocrat on A$1.37bn US acquisition
Allens has advised Aristocrat Leisure Limited ( Aristocrat ) on its A$1.37bn acquisition of Tennessee based Video Gaming Technologies, Inc. ( VGT ). Aristocrat will fund the acquisition and refinan ...
Discussion Paper: Biologic medicines and biosimilars in the Australian landscape - The challenges and the opportunities
Allens is engaging with stakeholders on the challenges and opportunities presented by biosimilars As part of this engagement we highlight a number of key issues for discussion and comment ...
Audio: D'Arcy v Myriad: The High Court rules on gene patenting
Allens Partner Dr Trevor Davies discusses why the High Court overturned the decision and what it means for the biotech industry ...
TGA confirms its approach to disclosure of commercially confidential information
The Therapeutic Goods Administration has released the final version of a document outlining its approach to the disclosure of commercially confidential information including information provided by medicine sponsors This follows the release of a draft version in June 2013 and a period of public and ...
Australia releases model for implementing the Nagoya Protocol
The Federal Government has released a model for the implementation of the Nagoya Protocol that will have major implications for those who use genetic resources and associated traditional knowledge for biodiscovery Partner Sarah Matheson and Lawyer Julieane Bull provide an overview of changes ...